Utilization of macrocyclic peptides to target protein-protein interactions in cancer
Protein-protein interactions (PPIs) play vital roles in normal cellular processes. Dysregulated PPIs are involved in the process of various diseases, including cancer. Thus, these PPIs may serve as potential therapeutic targets in cancer treatment. However, despite rapid advances in small-molecule d...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-11-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.992171/full |
| _version_ | 1797983632507273216 |
|---|---|
| author | Jiawen Yang Jiawen Yang Jiawen Yang Qiaoliang Zhu Yifan Wu Yifan Wu Yifan Wu Xiaojuan Qu Xiaojuan Qu Xiaojuan Qu Haixia Liu Haixia Liu Haixia Liu Biao Jiang Biao Jiang Di Ge Xiaoling Song |
| author_facet | Jiawen Yang Jiawen Yang Jiawen Yang Qiaoliang Zhu Yifan Wu Yifan Wu Yifan Wu Xiaojuan Qu Xiaojuan Qu Xiaojuan Qu Haixia Liu Haixia Liu Haixia Liu Biao Jiang Biao Jiang Di Ge Xiaoling Song |
| author_sort | Jiawen Yang |
| collection | DOAJ |
| description | Protein-protein interactions (PPIs) play vital roles in normal cellular processes. Dysregulated PPIs are involved in the process of various diseases, including cancer. Thus, these PPIs may serve as potential therapeutic targets in cancer treatment. However, despite rapid advances in small-molecule drugs and biologics, it is still hard to target PPIs, especially for those intracellular PPIs. Macrocyclic peptides have gained growing attention for their therapeutic properties in targeting dysregulated PPIs. Macrocyclic peptides have some unique features, such as moderate sizes, high selectivity, and high binding affinities, which make them good drug candidates. In addition, some oncology macrocyclic peptide drugs have been approved by the US Food and Drug Administration (FDA) for clinical use. Here, we reviewed the recent development of macrocyclic peptides in cancer treatment. The opportunities and challenges were also discussed to inspire new perspectives. |
| first_indexed | 2024-04-11T06:50:21Z |
| format | Article |
| id | doaj.art-894013eb975c4ac68afa43da5825f5f6 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-11T06:50:21Z |
| publishDate | 2022-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-894013eb975c4ac68afa43da5825f5f62022-12-22T04:39:14ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-11-011210.3389/fonc.2022.992171992171Utilization of macrocyclic peptides to target protein-protein interactions in cancerJiawen Yang0Jiawen Yang1Jiawen Yang2Qiaoliang Zhu3Yifan Wu4Yifan Wu5Yifan Wu6Xiaojuan Qu7Xiaojuan Qu8Xiaojuan Qu9Haixia Liu10Haixia Liu11Haixia Liu12Biao Jiang13Biao Jiang14Di Ge15Xiaoling Song16Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, ChinaShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, ChinaShanghai Clinical Research and Trial Center, Shanghai, ChinaDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, ChinaShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, ChinaSchool of Life Science and Technology, ShanghaiTech University, Shanghai, ChinaUniversity of Chinese Academy of Sciences, Beijing, ChinaShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, ChinaSchool of Life Science and Technology, ShanghaiTech University, Shanghai, ChinaUniversity of Chinese Academy of Sciences, Beijing, ChinaShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, ChinaUniversity of Chinese Academy of Sciences, Beijing, ChinaSchool of Physical Science and Technology, ShanghaiTech University, Shanghai, ChinaShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, ChinaSchool of Physical Science and Technology, ShanghaiTech University, Shanghai, ChinaDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, ChinaShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, ChinaProtein-protein interactions (PPIs) play vital roles in normal cellular processes. Dysregulated PPIs are involved in the process of various diseases, including cancer. Thus, these PPIs may serve as potential therapeutic targets in cancer treatment. However, despite rapid advances in small-molecule drugs and biologics, it is still hard to target PPIs, especially for those intracellular PPIs. Macrocyclic peptides have gained growing attention for their therapeutic properties in targeting dysregulated PPIs. Macrocyclic peptides have some unique features, such as moderate sizes, high selectivity, and high binding affinities, which make them good drug candidates. In addition, some oncology macrocyclic peptide drugs have been approved by the US Food and Drug Administration (FDA) for clinical use. Here, we reviewed the recent development of macrocyclic peptides in cancer treatment. The opportunities and challenges were also discussed to inspire new perspectives.https://www.frontiersin.org/articles/10.3389/fonc.2022.992171/fullprotein-protein interactionsmacrocyclic peptidecancertreatmentdrug |
| spellingShingle | Jiawen Yang Jiawen Yang Jiawen Yang Qiaoliang Zhu Yifan Wu Yifan Wu Yifan Wu Xiaojuan Qu Xiaojuan Qu Xiaojuan Qu Haixia Liu Haixia Liu Haixia Liu Biao Jiang Biao Jiang Di Ge Xiaoling Song Utilization of macrocyclic peptides to target protein-protein interactions in cancer Frontiers in Oncology protein-protein interactions macrocyclic peptide cancer treatment drug |
| title | Utilization of macrocyclic peptides to target protein-protein interactions in cancer |
| title_full | Utilization of macrocyclic peptides to target protein-protein interactions in cancer |
| title_fullStr | Utilization of macrocyclic peptides to target protein-protein interactions in cancer |
| title_full_unstemmed | Utilization of macrocyclic peptides to target protein-protein interactions in cancer |
| title_short | Utilization of macrocyclic peptides to target protein-protein interactions in cancer |
| title_sort | utilization of macrocyclic peptides to target protein protein interactions in cancer |
| topic | protein-protein interactions macrocyclic peptide cancer treatment drug |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.992171/full |
| work_keys_str_mv | AT jiawenyang utilizationofmacrocyclicpeptidestotargetproteinproteininteractionsincancer AT jiawenyang utilizationofmacrocyclicpeptidestotargetproteinproteininteractionsincancer AT jiawenyang utilizationofmacrocyclicpeptidestotargetproteinproteininteractionsincancer AT qiaoliangzhu utilizationofmacrocyclicpeptidestotargetproteinproteininteractionsincancer AT yifanwu utilizationofmacrocyclicpeptidestotargetproteinproteininteractionsincancer AT yifanwu utilizationofmacrocyclicpeptidestotargetproteinproteininteractionsincancer AT yifanwu utilizationofmacrocyclicpeptidestotargetproteinproteininteractionsincancer AT xiaojuanqu utilizationofmacrocyclicpeptidestotargetproteinproteininteractionsincancer AT xiaojuanqu utilizationofmacrocyclicpeptidestotargetproteinproteininteractionsincancer AT xiaojuanqu utilizationofmacrocyclicpeptidestotargetproteinproteininteractionsincancer AT haixialiu utilizationofmacrocyclicpeptidestotargetproteinproteininteractionsincancer AT haixialiu utilizationofmacrocyclicpeptidestotargetproteinproteininteractionsincancer AT haixialiu utilizationofmacrocyclicpeptidestotargetproteinproteininteractionsincancer AT biaojiang utilizationofmacrocyclicpeptidestotargetproteinproteininteractionsincancer AT biaojiang utilizationofmacrocyclicpeptidestotargetproteinproteininteractionsincancer AT dige utilizationofmacrocyclicpeptidestotargetproteinproteininteractionsincancer AT xiaolingsong utilizationofmacrocyclicpeptidestotargetproteinproteininteractionsincancer |